Time New York: Tue 19 Sep 11:21 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session

Zacks

Aldeyra Therapeutics, Inc. ALDX was a big mover last session, as the company saw its shares rise more than 34% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $3.90 to $4.30 in the past one month time frame.

The move came after the company reported positive results from the clinical trial of its Phase 2a of ADX-102 for patients with dry eye disease.

The company has seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Aldeyra Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Aldeyra Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.


Investors interested in the Medical – Drugs industry may consider Corbus Pharmaceuticals Holdings, Inc. CRBP, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ALDX going up? Or down? Predict to see what others think:Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.